{"id":4060,"date":"2018-05-16T21:47:33","date_gmt":"2018-05-16T21:47:33","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=4060"},"modified":"2020-12-13T18:14:09","modified_gmt":"2020-12-13T23:14:09","slug":"eiger-press-release-2","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/kk\/2018\/05\/16\/eiger-press-release-2\/","title":{"rendered":"JAMA \u0437\u0435\u0440\u0442\u0442\u0435\u0443\u0456\u043d\u0456\u04a3 \u04e9\u043a\u0448\u0435\u0441\u0456\u043d\u0434\u0435, PRF \u0436\u04d9\u043d\u0435 Eiger BioPharmaceuticals \u0441\u0435\u0440\u0456\u043a\u0442\u0435\u0441\u0456 FDA \u041b\u043e\u043d\u0430\u0444\u0430\u0440\u043d\u0438\u0431\u0442\u0456 \u043c\u0430\u049b\u04b1\u043b\u0434\u0430\u0443\u0493\u0430 \u04b1\u043c\u0442\u044b\u043b\u0430\u0434\u044b."},"content":{"rendered":"<p>[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d3.22\u2033][et_pb_row _builder_version=\u201d3.25\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201d\u049b\u0430\u0439\u0442\u0430\u043b\u0430\u0443\u201d][et_pb_co-4\u201d][et_pb_row\u201d _builder_version=\u201d3,25\u2033 custom_padding=\u201d|||\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.6.5\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d hover_enabled=\u201d0\u2033 sticky_enabled=\u201d0\u2033]<\/p>\n<p>\u042b\u043d\u0442\u044b\u043c\u0430\u049b\u0442\u0430\u0441\u0442\u044b\u049b \u041f\u0440\u043e\u0433\u0435\u0440\u0438\u044f\u043d\u044b \u0435\u043c\u0434\u0435\u0443\u0433\u0435 \u0430\u0440\u043d\u0430\u043b\u0493\u0430\u043d \u0430\u043b\u0493\u0430\u0448\u049b\u044b \u04b1\u0441\u044b\u043d\u044b\u0441\u0442\u044b \u0431\u0456\u043b\u0434\u0456\u0440\u0435\u0434\u0456. \u0415\u0433\u0435\u0440 \u043c\u0430\u049b\u04b1\u043b\u0434\u0430\u043d\u0441\u0430, \u0431\u0430\u043b\u0430\u043b\u0430\u0440 \u0434\u04d9\u0440\u0456-\u0434\u04d9\u0440\u043c\u0435\u043a\u0442\u0456 \u043a\u043b\u0438\u043d\u0438\u043a\u0430\u043b\u044b\u049b \u0441\u044b\u043d\u0430\u049b\u0442\u044b\u04a3 \u043e\u0440\u043d\u044b\u043d\u0430 \u0440\u0435\u0446\u0435\u043f\u0442 \u0431\u043e\u0439\u044b\u043d\u0448\u0430 \u0430\u043b\u0430 \u0430\u043b\u0430\u0434\u044b!!<\/p>\n<p>\u0411\u0456\u0437\u0434\u0456\u04a3 \u0441\u043e\u04a3\u0493\u044b \u0431\u0430\u0441\u043f\u0430\u0441\u04e9\u0437 \u0445\u0430\u0431\u0430\u0440\u043b\u0430\u043c\u0430\u043b\u0430\u0440\u044b\u043d \u043c\u044b\u043d\u0430 \u0436\u0435\u0440\u0434\u0435\u043d \u043e\u049b\u044b\u04a3\u044b\u0437:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/PRF-Eiger-FINAL-Press-release.pdf\">Progeria \u0437\u0435\u0440\u0442\u0442\u0435\u0443 \u049b\u043e\u0440\u044b Eiger BioPharmaceuticals \u043a\u043e\u043c\u043f\u0430\u043d\u0438\u044f\u0441\u044b\u043c\u0435\u043d \u044b\u043d\u0442\u044b\u043c\u0430\u049b\u0442\u0430\u0441\u0442\u044b\u049b \u0436\u04d9\u043d\u0435 \u0436\u0435\u0442\u043a\u0456\u0437\u0443 \u043a\u0435\u043b\u0456\u0441\u0456\u043c\u0456\u043d \u0436\u0430\u0440\u0438\u044f\u043b\u0430\u0439\u0434\u044b\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/04\/PRF-JAMA-Announcement_Press-Release-1.pdf\">JAMA-\u0434\u0430 \u0436\u0430\u0440\u0438\u044f\u043b\u0430\u043d\u0493\u0430\u043d \u0436\u0430\u04bb\u0430\u043d\u0434\u044b\u049b \u0437\u0435\u0440\u0442\u0442\u0435\u0443 \u041b\u043e\u043d\u0430\u0444\u0430\u0440\u043d\u0438\u0431\u043f\u0435\u043d \u0435\u043c\u0434\u0435\u0443 \u043f\u0440\u043e\u0433\u0435\u0440\u0438\u044f\u0441\u044b \u0431\u0430\u0440 \u0431\u0430\u043b\u0430\u043b\u0430\u0440\u0434\u0430 \u04e9\u043c\u0456\u0440 \u0441\u04af\u0440\u0443\u0434\u0456 \u04b1\u0437\u0430\u0440\u0442\u0430\u0434\u044b<\/a><\/li>\n<\/ul>\n<div id=\"attachment_9151\" style=\"width: 285px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-9151\" class=\"size-medium wp-image-9151\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/12\/getting-drug-zoeycarly-April-2016-1-275x300.jpg\" alt=\"\" width=\"275\" height=\"300\" \/><p id=\"caption-attachment-9151\" class=\"wp-caption-text\">\u0417\u043e\u0438 \u043c\u0435\u043d \u041a\u0430\u0440\u043b\u0438 \u0411\u043e\u0441\u0442\u043e\u043d\u0493\u0430 \u0441\u043e\u04a3\u0493\u044b \u043a\u043b\u0438\u043d\u0438\u043a\u0430\u043b\u044b\u049b \u0441\u044b\u043d\u0430\u049b \u0441\u0430\u043f\u0430\u0440\u044b \u043a\u0435\u0437\u0456\u043d\u0434\u0435 \u043b\u043e\u043d\u0430\u0444\u0430\u0440\u043d\u0438\u0431\u043f\u0435\u043d \u0435\u043c \u0430\u043b\u0443\u0434\u0430.<\/p><\/div>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>JAMA \u0437\u0435\u0440\u0442\u0442\u0435\u0443\u0456\u043d\u0456\u04a3 \u04e9\u043a\u0448\u0435\u0441\u0456\u043d\u0434\u0435, PRF \u0436\u04d9\u043d\u0435 Eiger BioPharmaceuticals \u0441\u0435\u0440\u0456\u043a\u0442\u0435\u0441\u0456 FDA \u041b\u043e\u043d\u0430\u0444\u0430\u0440\u043d\u0438\u0431\u0442\u0456 \u043c\u0430\u049b\u04b1\u043b\u0434\u0430\u0443\u0493\u0430 \u04b1\u043c\u0442\u044b\u043b\u0430\u0434\u044b. \t<\/p>","protected":false},"author":2,"featured_media":11817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<p>Collaboration marks the first submission for the treatment of Progeria. If approved, children may access drug by prescription instead of clinical trial!!<\/p><p>Read our latest press releases here:<\/p><ul><li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/PRF-Eiger-FINAL-Press-release.pdf\">Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals\u00a0<\/a><\/li><li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/04\/PRF-JAMA-Announcement_Press-Release-1.pdf\">Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria<\/a><\/li><\/ul>[caption id=\"attachment_9151\" align=\"aligncenter\" width=\"275\"]<img class=\"size-medium wp-image-9151\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/12\/getting-drug-zoeycarly-April-2016-1-275x300.jpg\" alt=\"\" width=\"275\" height=\"300\" \/> Zoey and Carly getting their lonafarnib treatment during their latest clinical trial visit to Boston.[\/caption]<p>\u00a0<\/p>","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-4060","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-news","post_format-post-format-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/kk\/2018\/05\/16\/eiger-press-release-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/kk\/2018\/05\/16\/eiger-press-release-2\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-16T21:47:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-13T23:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u043c\u0438\u043d\u0443\u0442\u0430\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib\",\"datePublished\":\"2018-05-16T21:47:33+00:00\",\"dateModified\":\"2020-12-13T23:14:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"},\"wordCount\":159,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"ru-RU\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\",\"name\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"datePublished\":\"2018-05-16T21:47:33+00:00\",\"dateModified\":\"2020-12-13T23:14:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb\"},\"inLanguage\":\"ru-RU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ru-RU\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"width\":300,\"height\":225},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ru-RU\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ru-RU\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ru-RU\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/kk\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/kk\/2018\/05\/16\/eiger-press-release-2\/","og_locale":"en_US","og_type":"article","og_title":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","og_description":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.","og_url":"https:\/\/www.progeriaresearch.org\/kk\/2018\/05\/16\/eiger-press-release-2\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2018-05-16T21:47:33+00:00","article_modified_time":"2020-12-13T23:14:09+00:00","og_image":[{"width":300,"height":225,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 \u043c\u0438\u043d\u0443\u0442\u0430"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib","datePublished":"2018-05-16T21:47:33+00:00","dateModified":"2020-12-13T23:14:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"},"wordCount":159,"commentCount":0,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","articleSection":["News"],"inLanguage":"ru-RU","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/","url":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/","name":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","datePublished":"2018-05-16T21:47:33+00:00","dateModified":"2020-12-13T23:14:09+00:00","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb"},"inLanguage":"ru-RU","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"]}]},{"@type":"ImageObject","inLanguage":"ru-RU","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","width":300,"height":225},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Progeria \u0437\u0435\u0440\u0442\u0442\u0435\u0443 \u049b\u043e\u0440\u044b","description":"\u0411\u0430\u043b\u0430\u043b\u0430\u0440\u0493\u0430 \u2665 \u0415\u043c\u0434\u0435\u0443 \u04af\u0448\u0456\u043d","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ru-RU"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Progeria \u0437\u0435\u0440\u0442\u0442\u0435\u0443 \u049b\u043e\u0440\u044b","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"ru-RU","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\u041a\u0430\u0440\u0435\u043d \u0411\u0435\u0442\u0443\u0440\u043d\u0430\u0439","image":{"@type":"ImageObject","inLanguage":"ru-RU","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/kk\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/posts\/4060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/comments?post=4060"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/posts\/4060\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/media\/11817"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/media?parent=4060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/categories?post=4060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/kk\/wp-json\/wp\/v2\/tags?post=4060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}